Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Astria Therapeutics (ATXS) Earnings Date, Estimates & Call Transcripts

Astria Therapeutics logo

Astria Therapeutics Earnings Summary

Astria Therapeutics posted Q3 2025 earnings on November 12, 2025, reporting an EPS of -$0.55, which missed the consensus estimate of -$0.41 by $0.14. Quarterly revenue was reported to be $0.71 million, below the consensus estimate of $10.67 million. With a trailing EPS of -$2.14, Astria Therapeutics' earnings are expected to decrease next year, from ($1.65) to ($1.78) per share.

Latest Q3
Earnings Date
Nov. 12Estimated
Consensus EPS
(Nov. 12)
-$0.41
Actual EPS
(Nov. 12)
-$0.55 Missed By -$0.14
Actual Revenue
(Nov. 12)
$0.71M

Q3 2025 Earnings Resources

Get Astria Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astria Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

ATXS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Astria Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20261-$0.48-$0.48-$0.48
Q2 20261-$0.49-$0.49-$0.49
Q3 20261-$0.51-$0.51-$0.51
Q4 20261-$0.52-$0.52-$0.52

Astria Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/12/2025Q3 2025-$0.41-$0.55 -$0.14-$0.55$10.67M$0.71M
8/12/2025Q2 2025-$0.61-$0.57+$0.04-$0.57$16.00M-
5/13/2025Q1 2025-$0.48-$0.58 -$0.10-$0.58--
3/11/2025Q4 2024-$0.45-$0.44+$0.01-$0.44--
8/12/2024Q2 2024-$0.38-$0.43 -$0.05-$0.43--
5/9/2024Q1 2024-$0.35-$0.38 -$0.03-$0.38--

Data powered by Fiscal.ai.

Astria Therapeutics Earnings - Frequently Asked Questions

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earning data on Wednesday, November 12, 2025. Learn more on ATXS's earnings history.

In the previous quarter, Astria Therapeutics (NASDAQ:ATXS) missed the analysts' consensus estimate of ($0.41) by $0.14 with a reported earnings per share (EPS) of ($0.55). Learn more on analysts' earnings estimate vs. ATXS's actual earnings.

Astria Therapeutics (NASDAQ:ATXS) has a recorded annual revenue of $706,000.00.

Astria Therapeutics (NASDAQ:ATXS) has a recorded net income of -$94.26 million. ATXS has generated -$2.14 earnings per share over the last four quarters.

Astria Therapeutics' earnings are expected to decrease from ($1.65) per share to ($1.78) per share in the next year.


This page (NASDAQ:ATXS) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners